Related Experiment Video
Updated: May 28, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Pestones A and B from a Fungus Pestalotiopsis sp. Bound to Mutant p53 and Changed Its Conformation
Yusaku Sadahiro1, Misaki Okubo1, Yuki Hitora1
1Department of Natural Medicines, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Abstract:
Oncogenic mutant p53 is one of the targets for cancer therapy, and the development of anticancer drugs that reactivate mutant p53 is a promising strategy. The extract of fungus Pestalotiopsis sp. changed mutant p53 to wild-type-like p53 in Saos-2 (p53R175H) cells, as shown by fluorescent immunostaining, and bioassay-guided purification of the extract afforded new dimeric epoxyquinoids, pestones A and B (1 and 2), and a known compound, rosnecatrone (3). The relative and absolute configurations of 1 and 2 were determined based on the spectroscopic data and semisynthesis from 3. Compounds 1 and 2 altered the conformation of mutant p53 in Saos-2 (p53R175H) cells, as shown by immunofluorescence staining. The cellular thermal shift assay analysis showed that 1 increased the thermostability of mutant p53 in Saos-2 (p53R175H) cells, suggesting the direct binding of 1 to mutant p53. Compounds 1 and 2 exhibited cytotoxic activities against Saos-2 (p53R175H) cells with IC50 values of 1.0 and 1.1 μM, respectively. Compound 1 was found to induce apoptosis in Saos-2 (p53R175H) cells by flow cytometry analysis and decreased tumor growth in vivo using a mouse model with HuCCT1 (p53R175H) cells.
Insights
Researchers discovered new compounds, pestones A and B, from the fungus *Pestalotiopsis* sp. These compounds reactivate mutant p53 (a cancer target) and show potent anticancer activity, offering a promising new cancer therapy strategy.
Area of Science:
- Natural Products Chemistry
- Cancer Biology
- Drug Discovery
Background:
- Oncogenic mutant p53 is a key target in cancer therapy.
- Developing drugs to reactivate mutant p53 is a promising therapeutic strategy.
- Fungal extracts represent a potential source for novel anticancer agents.
Purpose of the Study:
- To isolate and characterize compounds from *Pestalotiopsis* sp. with the ability to restore mutant p53 function.
- To evaluate the anticancer potential of isolated compounds against p53-mutated cancer cells.
- To investigate the mechanism of action of these compounds on mutant p53.
Main Methods:
- Bioassay-guided purification of *Pestalotiopsis* sp. extract.
- Spectroscopic analysis (NMR, MS) for structural elucidation.
- Cellular thermal shift assay (CETSA) and immunofluorescence staining to assess p53 interaction.
- Cytotoxicity assays (IC50 determination) and flow cytometry for apoptosis analysis.
- In vivo tumor growth inhibition studies in a mouse model.
Main Results:
- Isolation of two new dimeric epoxyquinoids, pestones A (1) and B (2), and known compound rosnecatrone (3).
- Pestones A and B were confirmed to alter mutant p53 conformation and compound 1 directly binds to mutant p53, increasing its thermostability.
- Compounds 1 and 2 demonstrated significant cytotoxic activity against Saos-2 (p53R175H) cells (IC50 values 1.0 and 1.1 μM).
- Compound 1 induced apoptosis in cancer cells and reduced tumor growth in vivo.
Conclusions:
- Pestones A and B are novel dimeric epoxyquinoids with the ability to reactivate mutant p53.
- These compounds exhibit potent anticancer activity through mechanisms involving p53 restoration, apoptosis induction, and tumor growth inhibition.
- Pestalotiopsis sp. derived compounds represent a promising new avenue for developing targeted cancer therapies against p53-mutated cancers.
Related Concept Videos
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Negative Regulator Molecules
Drugs that Destabilize Microtubules
DNA Damage can Stall the Cell Cycle
Drugs that Stabilize Microtubules

